Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) therapy(Qingdao Sino-Cell Biomedicine)

N/A

Report date: 2026/04/17 10:36:27

Base Information

Drug NameAdoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) therapy(Qingdao Sino-Cell Biomedicine)

Drug Alias NameHS-IT201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesQingdao Sino-cell Biomedicine Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesQingdao Sino-cell Biomedicine Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A